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Despite significant improvement in modalities for treatment of cancer that led to a longer
survival period, the death rate of patients with solid tumors has not changed during the last
decades. Emerging studies have identified several physical barriers that limit the therapeu-
tic efficacy of cancer therapeutic agents such as monoclonal antibodies, chemotherapeutic
agents, anti-tumor immune cells, and gene therapeutics. Most solid tumors are of epithelial
origin and, although malignant cells are de-differentiated, they maintain intercellular junc-
tions, a key feature of epithelial cells, both in the primary tumor as well as in metastatic
lesions. Furthermore, nests of malignant epithelial tumor cells are shielded by layers of
extracellular matrix (ECM) proteins (e.g., collagen, elastin, fibronectin, laminin) whereby
tumor vasculature rarely penetrates into the tumor nests. In this chapter, we will review
potential strategies to modulate the ECM and epithelial junctions to enhance the intratu-
moral diffusion and/or to remove physical masking of target receptors on malignant cells.
We will focus on peptides that bind to the junction protein desmoglein 2 and trigger intra-
cellular signaling, resulting in the transient opening of intercellular junctions. Intravenous
injection of these junction openers increased the efficacy and safety of therapies with
monoclonal antibodies, chemotherapeutics, and T cells in mouse tumor models and was
safe in non-human primates. Furthermore, we will summarize approaches to transiently
degrade ECM proteins or downregulate their expression. Among these approaches is the
intratumoral expression of relaxin or decorin after adenovirus- or stem cell-mediated gene
transfer. We will provide examples that relaxin-based approaches increase the anti-tumor
efficacy of oncolytic viruses, monoclonal antibodies, and T cells.
Keywords: epithelial junctions, tumor stroma, extracellular matrix, relaxin, junction opener, tumor-associated
macrophages
TUMOR MICROENVIRONMENT
TUMOR STROMA
Tumors are heterogeneous cellular entities in which progres-
sion depends on the crosstalk between the genetically abnormal
cells (the epithelial parenchyma of carcinomas) and the tumor
stroma (the supportive framework of a tumor tissue). This tumor
stroma is basically composed of the non-malignant cells (stro-
mal cells) of the tumor such as cancer-associated fibroblasts
(CAFs), immune cells [tumor-associated macrophages (TAMs)
and tumor-associated neutrophils (TANs)], and mesenchymal
stem cells as well as the extracellular matrix (ECM) consisting
of fibrous structural proteins (collagen and elastin), fibrous adhe-
sive proteins (fibronectin and laminin), and proteoglycans (1–3)
(Figure 1A). In most solid tumors derived from epithelial tissues,
nests of malignant tumor cells are linked through junction proteins
such as E-cadherin, claudins, and desmoglein 2 (DSG2). Tumor
nests are surrounded by tumor stroma (Figures 1B,C). The stroma
is indispensable for normal tissue development and homeostasis,
since it has a vital role in regulating behavior of cells residing in
the local milieu (4–7). Likewise, various components of the tumor
stroma create a niche favoring seeding of metastatic tumor cells.
More importantly, tumor stroma mediates the resistance to cancer
therapeutic agents (8–10). Tumor stroma contributes in at least
two critical ways to drug resistance: (i) by creating a physical bar-
rier formed by stroma proteins that prevents intratumoral drug
penetration and direct contact between drugs/tumor-infiltrating
immune effector cells and their target receptors on malignant cells
and (ii) by production of cytokines and chemokines that trigger
the synthesis of stroma proteins, block activation of immune cells,
or attract/activate immuno-suppressive cells such as regulatory T
cells (Tregs).
It is well established that stroma that is associated with normal
tissue development and homeostasis is strikingly distinct from
that associated with carcinomas (1). Specifically, the composi-
tion of tumor-derived ECM is different from normal ECM (11).
Excess ECM production or reduced ECM turnover are notice-
able in the majority of tumors (12, 13). Various collagens (e.g.,
collagen type I, II, III, V, and IX), fibronectin, tenasin C, and pro-
teoglycans exhibit increased accumulation and generate a dense
network in tumor tissues (14–17). Excessive deposition of ECM
components decreases the distance between neighboring ECM
components and diminishes the pore size of the tumor matrix.
This adds diffusional impediment to macromolecules (IgG, IgM,
and dextran 2,000,000 MW) in tumors (18). A strong inverse
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FIGURE 1 |Tumor stroma. (A) Schematic representation of tumor
stroma components. The tumor stroma is composed of stromal cells
(fibroblasts, macrophages, neutrophils, and mesenchymal stem cells)
as well as extracellular matrix. (B) Sections from breast cancer
patient biopsies (stage III and IV). DSG2 staining appears in brown.
Malignant cells are DSG2-positive and form nests that are surrounded
by tumor stroma containing DSG2-negative stroma cells such as
fibroblasts. (C) Immunofluorescence analysis for Her2/neu (green)
and the stroma protein laminin (red) on a breast cancer section. The
scale bar is 20µm.
correlation between tumor ECM content and tumor penetration
of cancer drugs has been demonstrated for therapeutic agents such
as anti-tumor immune cells, therapeutic viruses, chemotherapeu-
tic agents, monoclonal antibodies, immunotoxins, interferons, and
complement (18–24). Due to increased ECM deposition, tumor
tissue commonly exhibits increased stiffness compared to normal
tissue. For breast cancer, tumor tissue was found to be 10 times
stiffer than normal breast tissue (26, 27). The elevated ECM stiff-
ness progressively increases interstitial fluid pressure (IFP) which
thereafter interferes with effective spread of anti-cancer therapeu-
tics within the solid tumor (28–30). In summary, the deregulation
and disorganization of the tumor stroma alter the composition,
structure, and stiffness of the ECM, leading to limited penetration
and dissemination of therapeutic agents within solid tumors.
Killing the genetically stable tumor stroma cells has definitive
advantages over targeting the malignant cells, i.e., cells that are
genetically unstable and heterogeneous and represent a moving
target for therapies.
TUMOR STROMAL CELLS
The major contributors of abnormal ECM in solid tumors are
stromal cells such as cancer-associated fibroblasts (CAFs), TAMs,
and TANs (3, 13, 31). These stromal cells display sustained synthe-
sis and secretion of connective tissue components, growth factors,
and cytokines, which promote the ability of malignant cells to pro-
liferate, invade, and metastasize (32, 33). Thus targeting the tumor
stromal cells is considered a promising approach to the treatment
of cancer.
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Cancer-associated fibroblasts
Cancer-associated fibroblasts are the predominant cell type in the
tumor-associated stroma. Their numbers are elevated in tumor
stroma compared to stroma found in healthy tissue (34, 35). In
many carcinomas, the fraction of CAFs is even greater than the
fraction of malignant cells (32). In the tumor microenvironment,
tumor and stromal cells upregulate various profibrotic growth
factors such as transforming growth factor-β (TGF-β), platelet-
derived growth factor (PDGF), and basic fibroblast growth factor
(bFGF), all of which are main mediators for the transdifferenti-
ation of stromal fibroblasts into CAFs (36, 37). CAFs are pheno-
typically and functionally distinct from normal stromal fibroblasts
(38). CAFs are large spindle-shaped mesenchymal cells that share
morphological characteristics of both smooth-muscle cells and
fibroblasts (39). Metabolically, CAFs are perpetually activated,
proliferate faster, and accumulate greater amounts of ECM con-
stituents than fibroblasts in normal tissues (2, 32, 40). In addition
to creating tumor-derived ECM, CAFs have an impact on can-
cer cell proliferation, invasion, and metastasis through secretion
of different growth factors [epidermal growth factor (EGF), FGF,
hepatocyte growth factor (HGF), and insulin-like growth factor-
1 (IGF-1) (2, 3, 31, 34, 41–44)]. CAFs are also involved in the
activation of angiogenic programs as well as the recruitment of
inflammatory cells (45). Local expression of vascular endothelial
growth factor (VEGF) or monocyte chemoattractant protein-1
(MCP-1) by CAFs stimulates angiogenesis and the recruitment of
pro-tumor myeloid cells.
TAMs and TANs
As another major component in the tumor stroma, TAMs have
emerged as a significant player in the stromal compartment of
virtually all types of carcinoma (46). While type M1 macrophages
are antigen-presenting cells that incite T cells to mount immune
responses, TAMs are M2-type macrophages and tumor promot-
ing. Tumor cells, among other cytokines, produce MCP-1 and
colony stimulating factor-1 (CSF-1) which participates in mobi-
lization of TAM-progenitors from the bone marrow and homing
to tumor stroma. Homing of TAMs to tumors is also supported
by the specific architecture of tumor blood vessels which pro-
mote efficient trafficking of blood cells. There is convincing evi-
dence that the extent of MCP-1 expression in human cancers
correlated with both TAM infiltration and tumor malignancy
(47–53). TAMs contribute to tumor-associated alteration in the
ECM by releasing profibrotic growth factors, which then act in an
autocrine and/or paracrine manner to differentiate normal stro-
mal fibroblasts into CAFs (33, 37, 46). TAMs also produce growth
factors (EGF, HGF, bFGF, and VEGF), cytokines [IL-1, IL-8, and
tumor necrosis factor-α (TNFα)], and enzymes [MMP-2, MMP-
7, MMP-9, MMP-12, and cyclooxygenase-2 (COX-2)] (46, 54).
Additionally, TAMs can suppress anti-tumor immune responses.
For example, TAMs secret a distinctive set of cytokines (IL-10
and TGF-β) as well as chemokines [chemokine (C–C motif) lig-
and (CCL)17, CCL22, and CCL24] favoring recruitment of Tregs
and generation of an immune suppressive microenvironment (55–
57). As outlined in Section“Epithelial-to-Mesenchymal Transition
and Mesenchymal-to-Epithelial Transition in Cancer,” TAMs also
promote epithelial-to-mesenchymal transition (EMT) via TGF-β
(58) and regulate cancer stem cell (CSC) activities (59) in solid
tumors.
Tumor-associated neutrophils comprise another prominent
portion of the immune cell infiltrates observed in a wide vari-
ety of murine models and human cancers (60–63). Similar to
TAMs, products secreted from neutrophils, including reactive oxy-
gen species, cytokine (IL-8), growth factors (VEGF and HGF),
and proteinases [arginase (ARG 1), MMP-2, MMP-8, MMP-9, and
MMP-13], have defined and specific roles in both regulating tumor
cell proliferation, angiogenesis, and metastasis and suppressing the
anti-tumor immune response (64).
TUMOR VASCULARIZATION
Transendothelial transport
Once systemically administered drugs reach the tumor sites, they
have to exit the tumor vasculature and translocate through the
interstitial space in order to reach their target cells. The endothe-
lial cell layer, lining the blood vessels, is thought to present a
barrier to macromolecular drugs (20). Transendothelial transport
of macromolecular drugs involves a phenomenon known as the
enhanced permeability and retention (EPR) effect in solid tumors.
The EPR effect is observed for intravenously administered macro-
molecular anti-cancer drugs that escape renal clearance, due to
their large molecular size (10–500 nm). They are mostly unable to
pass the tight endothelial junctions of normal blood vessels, but
can extravasate and then become trapped in the tumor vicinity
(65). Unlike normal tissues that feature an organized vascular net-
work, the blood vessel system in solid tumors is rather chaotic. The
endothelial cell layers are poorly aligned (66) and elevated levels of
vascular permeability factors generate “leaky” capillaries (65). It is
therefore thought that transendothelial transport is not a critical
limiting obstacle for large sized drugs.
Intratumoral pressure
Rapid tumor cell proliferation and weakly developed lymphatics
cause high IFP (67, 68) and blood vessel remodeling by intus-
susception (69) or compression (70). Additionally, the increased
hydraulic conductivity of “leaky” capillaries can further increase
the IFP in tumors (71). Together, this leads to an imbalance in
blood flow and nutrient supply within the tumor microenviron-
ment. The uniformly high IFP in the center of solid tumors drops
toward the periphery (72), which could negatively affect drug
extravasations in the high-pressure regions. Cells that are distant to
blood vessels (100–200µm) and located in high-pressure regions
subsequently constitute large areas of hypoxic, necrotic, or semi-
necrotic tissue. This exacerbates the tendency of tumor cells to
overproduce and release lactic acids within these regions, which
results in acidosis (73). Moreover, the vascular surface area per
unit tissue weight is decreasing with tumor growth, which further
limits transvascular exchange for large tumors when compared
to small tumors (74, 75). In contrast, cells situated in the inva-
sive front benefit from the enhanced vascular permeability that
supplies adequate amounts of macromolecules for rapid tumor
growth (76). Furthermore, the blood flow rates in non-necrotic
regions can be substantially higher than in the surrounding nor-
mal tissue (77). It is therefore expected that the uptake of drugs in
solid tumors is heterogeneous and the general distribution might
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decrease with increasing tumor weight. It is thought that induc-
tion of massive cell death by chemo- and radio-therapy can lower
the IFP in tumors (78). The application of chemotherapy to lower
the IFP is also used in approaches to “normalize” the tumor vas-
culature. Anti-angiogenic drugs are thought to compensate for
the pro-angiogenic factors that are extensively produced in the
tumor in order to eliminate “leaky” blood vessels. Ideally, this
would lead to a more organized blood vessel system that fea-
tures more functional and more uniformly perfused capillaries
within solid tumors. On the other hand, this would also inhibit
the extravasation of large drugs.
Hypoxia
Two major consequences of abnormal microcirculation in solid
tumors are hypoxia and low extracellular pH. Hypoxia or oxygen
deprivation is a key factor in tumor progression and resistance
to therapy. The most important regulatory factor of the hypoxia-
signaling pathway activity in cells is hypoxia-inducible transcrip-
tion factor 1 (HIF-1α). Under hypoxic condition, tumors produce
a number of chemokines that attract and differentiate CAFs,
TAMs, and TANs. Approaches that reduced intratumoral hypoxia
therefore block pro-tumoral functions of these cells, including
the production of stroma proteins. It is therefore thought that
hypoxia targeting strategies improve the intratumoral penetration
of drugs (79).
EPITHELIAL PHENOTYPE OF SOLID TUMORS
EPITHELIAL JUNCTIONS
About 90% of solid tumors are of epithelial origin, often featur-
ing a stratified epithelium characterized by multilayered cells with
three-dimensional intercellular junctions. This is in contrast to
monolayered epithelial cells lining epithelial tracts (e.g., airway,
gastrointestinal, and urinary tracts), epithelial ducts (e.g., bile and
pancreatic ducts), or cavities (e.g., brain ventricles), which possess
an apical-basal polarization of their cell membranes and cytoskele-
ton. The epithelial phenotype is generally defined by tight and
adherence junctions that seal the paracellular space between adja-
cent cells and thereby providing a barrier that restricts passing of
ions and macromolecules (Figure 2A) (80).
Tight junctions (zonula occludens)
Tight junctions play a key role in the formation of epithelial sheets.
Strictly linked to tight junctions is a barrier function within a sheet
of cells that restricts ions and small molecules to pass through
the paracellular space between two adjacent epithelial cells (80).
Additionally, tight junctions function as a “fence” that separates
the apical and basal membrane compartments in an individual cell
(81). Importantly, the tight junction strands on one cell are associ-
ated laterally to tight junction strands of opposing membranes on
neighboring cells (82). The permselective barrier function is based
on occludins and claudins, two types of transmembrane proteins
that have been identified among more than 40 proteins within tight
junctions (81, 83). Other tight junction transmembrane proteins
comprise the singlespan junctional adhesion molecules (JAMs) or
coxsackie and adenovirus receptor (CAR) (83–86) and the lately
identified tetraspan tricellulin, which is enriched in areas where
three cells meet (86).
Adherens junctions (zonula adherens)
The major transmembrane proteins of adherens junctions are
classical cadherins, such as epithelial cadherin (E-cadherin). Mem-
bers of this protein superfamily promote homophilic intercellular
adhesion in a Ca2+-dependent manner. Their cytoplasmic domain
binds cytosolic catenins that link the cadherin/catenin complex to
the actin cytoskeleton. The formation of adherens junctions con-
sequently leads to the assembly of tight junctions, but E-cadherin
is dispensable for tight junction maintenance (87). A central role in
maintenance and initiation of an epithelial phenotype is attributed
to E-cadherin, the core protein of adherens junctions. In addition
to its homophilic intercellular adhesive features, the extracellu-
lar E-cadherin domain functions as a direct repressor of receptor
tyrosine kinase (RTK) signaling via blockage of FGF or EGF ligand
binding stimulation (88, 89). The cytoplasmic part of E-cadherin
connects to the actin cytoskeleton and also influences a number
of signaling pathways via direct binding to p120- and β-catenin.
When adjunct to E-cadherin at the membrane, β-catenin inhibits
cell growth (90), whereas its translocation to the nucleus activates
canonical Wnt signaling (91). Similarly, p120-catenin stabilizes E-
cadherin at the membrane, while blocking NF-κB and Ras-MAPK
signaling (92, 93).
Desmosomal junctions/desmosomes (macula adherens)
Desmosomes are molecular complexes of cell adhesion proteins
and linking proteins that attach the cell surface adhesion proteins
to intracellular keratin cytoskeletal filaments. The cell adhesion
proteins of the desmosome, desmoglein, and desmocollin, are
members of the cadherin family of cell adhesion molecules. They
are transmembrane proteins that bridge the space between adja-
cent epithelial cells by way of homophilic binding of their extracel-
lular domains to other desmosomal cadherins on the adjacent cell.
Both have five extracellular domains, and have calcium-binding
motifs. One of these junction proteins, DSG2, is upregulated in
malignant cells (94, 95). DSG2 contains four extracellular cadherin
domains (ECDs; ECD1–ECD4), which link neighboring cells to
each other through homodimers. ECDs are linked via an extracel-
lular anchor and membrane-spanning domain to the intracellular
anchor and intracellular cadherin-typical sequence (ICS) motifs.
The role of the conserved ICS is not known, although consensus
sites for protein kinase C phosphorylation and a caspase-3 cleav-
age site have been identified and could contribute to signaling
(96). Desmosomes probably do not directly regulate paracellular
permeability, but they seem to do this indirectly by altering the
structure and the stability of tight junctions (97).
BLOCK OF INTRATUMORAL DIFFUSION OF MACROMOLECULES
One of the key features of epithelial tumors is the presence of
intercellular junctions, which link cells to one another, and act as
barriers to the penetration of molecules with a molecular weight of
>400 Da (98–100). Most of commonly used chemotherapy drugs
are either nanoparticle-based or encapsulated into liposomes with
diameter greater than 100 nm. For example, nanoparticle albumin
bound paclitaxel/nab-paclitaxel/Abraxane™ has an effective diam-
eter of 130 nm and liposomal doxorubicin/Doxil™ has a size of
90 nm. Even non-encapsulated chemotherapy drugs have a molec-
ular weight of greater 400 Da (for example: paclitaxel/Taxol™: MW
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FIGURE 2 | Architecture of epithelial cells. (A) Adjacent epithelial cells
maintain several intercellular junctions and an apical-basal polarity. Tight
junctions seal the paracellular space close to the apical side. Initial cell contact
is initiated by cadherins in the adherens junction complex that is situated
underneath tight junctions. Adherens junction complexes encircle cells as an
adherens belt, which connects to the F-actin cytoskeleton. Desmosomes are
spot-like adhesions randomly arranged on lateral sides of plasma membranes.
A key desmosomal junction protein is desmoglein 2 (DSG2). (B) Target
receptors for cancer therapy are often trapped in epithelial junctions. Shown
are breast cancer cells stained for Her2/neu (the target receptor for
trastuzumab/Herceptin™) and the junction protein claudin 7. The merged
image shows colocalization of both proteins in junctions between cells.
856.9 Da or irinotecan/Camptosar™: MW 586.7 Da). Several stud-
ies have shown that upregulation of epithelial junction proteins
correlated with increased resistance to therapy, including therapy
with the two major classes of cancer drugs – monoclonal antibod-
ies and chemotherapeutics (101–103). It is thought that the epithe-
lial phenotype of cancer cells and their ability to form physical
barriers protect the tumor cells from attacks by the host-immune
system or from elimination by cancer therapeutics (104).
INACCESSIBILITY OF THERAPY TARGET RECEPTORS
Receptors for therapeutic antibodies are often localized at the baso-
lateral membrane of epithelial cells. This includes Her2/neu (105,
106) and EGFR (107, 108). In our studies on epithelial tumors we
found that target receptors are trapped in intercellular junctions
(109). For example, Her2/neu, the receptor for the widely used
monoclonal antibody Herceptin (trastuzumab) co-stained with
the tight junction proteins claudin 7 (Figure 2B).
EPITHELIAL-TO-MESENCHYMAL TRANSITION AND
MESENCHYMAL-TO-EPITHELIAL TRANSITION IN CANCER
Epithelial-to-mesenchymal transition and mesenchymal-to-
epithelial transition (MET) are important mechanisms that drive
tumor progression and therapy resistance, and indirectly affect
intratumoral drug penetration. EMT and MET have been accred-
ited important roles in embryogenic development, tissue regen-
eration, cancer progression, and recently also the induction and
maintenance of stem cell properties (110). Importantly, the phe-
notypic switches between epithelial and mesenchymal phenotypes
are not irreversible, as they occur several times during formation
of the complex three-dimensional structure of internal organs. In
contrast to epithelial cells, mesenchymal cells exhibit an irregular
shape, which is based on unpolarized cytoskeletons and mem-
branes. Further mesenchymal traits include the deposition of ECM
components, increased motility, invasiveness, as well as elevated
resistance to apoptosis and anoikis (110). EMT engages a series
of events involving inter- and intra-cellular changes in affected
cells. Importantly, not all of which have to occur during the trans-
differentiation process. Often cells remain in stages referred to
as an “incomplete” EMT, suggesting a spectrum of intermediate
stages rather than a strict lineage switch (104). Examples of such
epithelial/mesenchymal (E/M) hybrid cells have been reported for
multiple tissues including the ovarian surface epithelium (111),
ovarian cancer (25), cells within the invasive front of colon (112)
and breast cancer (113), as well as in normal epidermal tissue
during wound healing (114).
EMT and induction of tumor ECM proteins
During progression toward metastatic disease carcinoma cells
engage EMT. The EMT program can be activated by a multitude
of factors secreted by tumor stroma cells, which triggers a complex
signaling network including TGF-β, Wnt, HGF, EGF, and PDGF
pathways (115). The morphological changes that occur during
EMT are a consequence of diverse molecular mechanisms that
contribute to the acquisition of mesenchymal features. A central
event during EMT is the functional loss of E-cadherin. Subsequent
breakdown of intercellular epithelial junctions plays a major role
in cancer progression, where E-cadherin therefore acts as a repres-
sor of invasion (116). Accordingly, the reduced expression of this
major regulator of the epithelial phenotype is associated with poor
prognosis in several cancers (117). The loss of E-cadherin and
several other epithelial genes including multiple members of the
claudin family as well as occludin is mainly regulated via tran-
scriptional repression by EMT inducers that include transcription
factors Snail, ZEB, Twist, FOXC2, and E47 (118–126). Notably,
these EMT inducers also act as positive regulators of gene expres-
sion for several mesenchymal genes (127, 128). A consequent event
in EMT is the change from E-cadherin to N-cadherin (129). The
importance of this cadherin switch is highlighted by the fact that
homophilic intercellular junctions formed by N-cadherin are less
resistant to rupture under physiological stress conditions, when
compared with E-cadherin (130). Additionally, a shift from several
keratins (-8, -9, and -18) to vimentin occurs, resulting in a more
flexible cytoskeleton (131, 132). Concomitantly with the acquisi-
tion of such mesenchymal features, the expression of several ECM
proteins is induced. Fibronectin, collagen precursors, laminin, and
vitronectin are all reported to be elevated in mesenchymal cells
(133). These and other proteins, including Src kinase, integrin-
linked kinase, integrin β-5, and MMPs, are upregulated during
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EMT, have an impact on cytoskeletal remodeling, and promote
cell motility (104).
MET and cancer stem cells
Successful EMT induction ultimately enables cancer cells to leave
the primary tumor, enter the bloodstream, and attach to distant
organ sites in order to build metastases. The endpoint of this
process however, involves the reversed process (MET), where cells
that underwent EMT regain epithelial properties and form tumors
that histopathologically resemble the primary cancer (110, 134).
Although the underlying mechanisms are currently unknown, it
is likely that MET events are initiated due to the lack of EMT-
inducing signals at attachment sites of metastatic tumor cells. In
support, numerous examples of advanced carcinomas exist, show-
ing that mesenchymal cells can regain characteristics of epithelial
cells or undergo MET (104). It is now generally accepted that
the reverting to an epithelial phenotype through MET repre-
sents a protective mechanism against host-immune attacks and
creates resistance to anti-cancer drugs. The transdifferentiation
into an epithelial phenotype and the formation of tight junctions
between malignant cells that prevent penetration of host anti-
tumor immune cells, host anti-tumor antibodies, and therapeutics
represents one of the most basic cancer resistance mechanisms.
Importantly, changes between EMT and MET occur gradu-
ally, which leads to a wide range of intermediate cell stages that
consequently possess an E/M hybrid phenotype. The E/M hybrid
phenotype is especially prominent in the invasive front of several
carcinomas where it has also initially been linked to cells with a
stem cell-like phenotype (112, 113). We have recently shown in
cancer cells derived from ovarian cancer biopsies that CSCs gener-
ate mesenchymal cells via EMT in vitro and undergo MET to form
tumors containing epithelial cells when injected into immunode-
ficient mice (135). A marker combination widely used to identify
CSCs in multiple cancers including prostate, pancreatic, and colon
is EpCAM and CD44 (136, 137). Interestingly, the expression
of these proteins can be accredited to epithelial and mesenchy-
mal cells, respectively, suggesting a more general pattern of an
E/M hybrid phenotype for tumor-initiating cells (TICs) (25). Very
recently, work by Yu et al. demonstrated that cells, which leave the
primary tumor, possess an epithelial or E/M hybrid phenotype.
In the bloodstream these circulating tumor cells are bound by
platelets, which trigger EMT via TGF-β signaling (138). However,
cells undergoing EMT that leave the primary tumor experience
a proliferation arrest, which is mediated by EMT inducers, like
Twist1. In order to reenter a proliferative stage that allows for
colonization and macrometastasis, the downregulation of Twist1
and concomitant MET is critically needed, while ongoing EMT
signaling leads to dormancy and micrometastases at sites of reat-
tachment (139). Additionally, it was recently reported that two
distinct types of EMT exist in carcinomas, depending on the
presence or absence of EMT inducer paired-related homeobox
transcription factor 1 (Prrx1). When Prrx1 is expressed in cells
undergoing Twist1-induced EMT, a CSC pattern is suppressed and
cells fail to colonize. After Prrx1 is downregulated and other EMT
inducers, such as Twist1 or ZEB1 have vanished, MET occurs and
metastatic growth can be initiated (140). Notably, MET has also
been reported in non-epithelial cancers, e.g., sarcoma (141, 142).
STRATEGIES TO DEGRADE TUMOR ECM PROTEINS OR
DOWNREGULATE THEIR EXPRESSION
Tumor-derived ECM plays an important role in inhibiting pene-
tration and dispersion of cancer therapeutic agents within tumor
masses and has been implicated in resistance to therapy of solid
tumors (143). This has been shown for therapeutic modalities such
as oncolytic Ads (21), antibodies (18, 19), immunotoxins (24),
interferons (23), or complement (144). A series of approaches
have been tested to partially degrade ECM proteins and improve
the penetration of macromolecules and nanoparticle-based drugs.
(i) The first type of approaches involves the intratumoral injection
of proteases that can target ECM proteins. These proteases include
trypsin, collagenase, hyaluronidase, MMPs, relaxin, and decorin.
For example, intratumoral injection of collagenase has been shown
to remove diffusive hindrance to the penetration of therapeutic
molecules in subcutaneous human osteosarcoma and glioblas-
toma multiforme xenografts (145, 146). Similar approaches have
been tested in combination with cancer virotherapy, including Ads
(diameter:∼100 nm) and herpes simplex virus (HSV) (diameter:
∼190 nm). These viruses represent prototypes of nano-particles
and lessons learned from studies with oncolytic viruses are relevant
for other large anti-cancer drugs. Direct injection of subcuta-
neous human glioblastoma multiforme tumor with a proteolytic
enzyme (trypsin) or a protease mixture (collagenase/dispase)
before intratumoral injection with reporter gene-expressing Ad
vector elicited enhanced virus-mediated gene expression within
the solid tumor (147). Intratumoral co-injection of collagenase
with an oncolytic HSV vector in a human melanoma xenograft
resulted in increased intratumoral viral spread and therapeutic
benefit (148). Likewise, co-delivery of hyaluronidase and oncolytic
Ads led to improved intratumoral diffusion and virus potency
through degradation of hyaluronan-rich ECM in human prostate
and melanoma xenograft models (149). (ii) The second approach
involves the delivery of a protease-encoding gene expression cas-
sette to tumors. Cheng et al. generated replication-incompetent
Ads expressing MMP-8 that breaks down collagen type I, II,
and III in subcutaneous human A549 lung cancer and BxPC-
3 pancreatic cancer xenograft tumors (150). In studies testing
MMP-8-expressing Ads, MMP-8 expression efficiently degraded
collagen in vitro. Furthermore, co-injection of MMP-8-expressing
Ads in combination with wild-type Ads resulted in reduced tumor
cell growth and collagen expression within areas of virus-induced
necrosis compared with wild-type Ad given together with a control
Ad vector. Moreover, Mok et al. showed that intratumoral expres-
sion of MMP-1 and MMP-8 in the human HSTS26T soft tissue
sarcoma xenograft degraded collagen, reduced the levels of sul-
fated proteoglycans, and increased spread and effectiveness of an
oncolytic HSV (151). While degradation of ECM with enzymes,
such as collagenase and MMPs, may improve viral penetration
and distribution, there is a concern that this strategy may also
increase tumor spread; MMPs and collagenase play an impor-
tant role in tumor invasion and metastasis, which might limit
the use of these proteins in a clinical setting (152, 153). There-
fore, further thorough and detailed studies are required to gain
an improved understanding of the potential risk associated with
combined replicating oncolytic virus and ECM-degrading enzyme
or protein therapy.
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Our laboratories have tested approaches involving the expres-
sion of relaxin (154–157) or decorin (158). We will therefore
describe these approaches in more detail.
RELAXIN-BASED APPROACHES TO INCREASE DRUG PENETRATION IN
SOLID TUMORS
Relaxin is an insulin-related peptide hormone (159). During preg-
nancy, relaxin has an integral role in softening the uterine cervix,
vagina, and interpubic ligaments in preparation for parturition
(160). Relaxin is the ligand for two leucine-rich repeat-containing
G protein coupled receptors (LGRs), LGR7, and LGR8, now clas-
sified as relaxin family peptide receptors 1 and 2 (RXFP1 and
RXFP2), respectively (161). These receptors have been found on
relaxin target tissues, particularly on endometrial stromal cells
and CAFs (161). Binding of relaxin to these receptors triggers
intracellular signaling resulting in downregulation of ECM pro-
tein expression and upregulation of MMPs, which degrade stroma
proteins. Importantly, relaxin decreases the synthesis of collagens
and increases the expression of MMPs when collagen is abnormally
upregulated, but it does not significantly alter basal levels of colla-
gen expression, in contrast to other collagen-modulatory cytokines
(e.g., interferon-γ) (162). This implies that relaxin acts predomi-
nantly on tissues with increased ECM protein expression such as
fibrotic tissues and tumors. In agreement with these observations,
earlier reports showed that relaxin expression mediated by an Ad
vector reversed cardiac fibrosis without adversely affecting nor-
mal collagen levels in other organs in a transgenic murine model
of cardiac fibrosis (163). Relaxin has been used for degradation of
tumor-derived ECM components (164). In immunodeficient mice
bearing human HSTS26T soft tissue sarcomas in dorsal skinfold
chamber, chronic relaxin treatment via osmotic pumps elicited
improved collagen down-regulation and intratumoral dispersion
of macromolecules in tumor tissues, whereby the new tumor
ECM, that is generated after relaxin treatment, was more porous
and had a decreased diffusive resistance (145). In vitro studies
with human OHS osteosarcoma multicell spheroids, recombinant
relaxin increased the diffusion of the 150 kDa FITC-dextran, in
part, due to increased production of collagenase (146). Similar
results were reported in in vivo tumor models after intratumoral
injection of recombinant relaxin (145). In cancer virotherapy stud-
ies, relaxin was demonstrated to enhance tumor penetration and
dispersion of oncolytic Ad, thereby eliciting improved cancer gene
therapy (155) (Figure 3). In this study, the growth of both sub-
cutaneous xenograft (human glioma, hepatocellular carcinoma,
cervical carcinoma, and lung carcinoma) and orthotopic tumors
(human hepatocellular carcinoma) treated with relaxin-expressing
oncolytic Ad was markedly inhibited compared to tumors treated
with control oncolytic Ad that did not express relaxin. When
viral persistence and distribution was confirmed by immunohis-
tochemical studies, more Ad particles were observed across wider
areas of tumor tissues treated with relaxin-expressing oncolytic
Ad. Moreover, the collagen content of tumor tissues was reduced
significantly by relaxin-expressing oncolytic Ad without affecting
adjacent normal tissue. A relaxin-expressing oncolytic Ad contain-
ing Ad5/35 chimeric fibers in a subcutaneous human A375-mln1
malignant melanoma xenograft model also exhibited increased
viral spread and transduction efficiency through the tumor mass
and thereby increased anti-tumor efficacy and overall survival in
metastatic tumor models (154).
Access of anti-tumor immune cells and their intratumoral infil-
tration is limited by tumor stroma (19). More specifically, the
tumor stroma contributes to tumor immune escape by creating a
physical barrier formed by ECM components that restricts direct
physical contact between tumor-infiltrating anti-tumor immune
cells and cancer cells. As an approach to overcome this limita-
tion, Li et al. showed that the inducible intratumoral expression of
relaxin through the transplantation of mouse hematopoietic stem
cells transduced with a relaxin-expressing lentivirus vector led to
suppressed tumor growth in an immunocompetent mouse breast
cancer model (157). The therapeutic mechanism of the anti-tumor
effect is associated with the degradation of tumor stroma mediated
by relaxin and enhanced anti-tumor immune responses mediated
by better intratumoral infiltration of anti-tumor immune cells.
The same investigators also tested whether intratumoral relaxin
expression facilitates transplanted anti-tumor T cells to control
tumor growth. In a breast cancer model, they demonstrated that
relaxin augmented the efficacy of neu-targeted adoptively trans-
ferred T cells, and improved survival of mice with neu-expressing
mammary tumors. At day 33, in the T cell transplanted group, 25%
of the mice were alive. Combined with relaxin expression, survival
increased to 62.5%. Relaxin expression combined with naïve T
cell treatment also increased survival (37.5%), compared to naïve
T cell treatment alone (0%). Better survival of relaxin-expressing
mice was due to a higher number of neu-specific T cells inside the
tumor.
Tumor ECM as well as tumor cell density can inhibit diffu-
sional transport of monoclonal antibody therapeutics in tumor
tissues. In a study of the monoclonal antibody trastuzumab (Her-
ceptin) penetration, Beyer et al. observed extensive tumor ECM
and intercellular junctions in breast cancer patients and xenograft
models (156). Therefore, the authors hypothesized that this hin-
ders the access to Her2/neu and/or the intratumoral dispersion of
trastuzumab. They showed that hematopoietic stem cell-mediated
intratumoral relaxin expression in combination with trastuzumab
therapy resulted in a decrease of ECM proteins and a significant
delay of tumor growth, indicating that a stem cell-based approach
for relaxin expression in tumors facilitates tumor ECM degrada-
tion and substantially enhances effectiveness of antibody therapy
of cancer.
In all of these studies, relaxin expression did not induce metas-
tasis. In fact, it reversed the spread of tumor cells that normally
would metastasize. The latter is in conflict with earlier studies by
Silvertown et al. reporting that permanent relaxin overexpression
increased in vivo prostate xenograft tumor growth and angiogen-
esis (165). These results were recently revised by the same group
(166). While short-term exposure of tumor cells to relaxin in vitro
seems to enhance invasiveness (167), long-term exposure reduces
it (168). The general consensus is that relaxin expression alone is
not sufficient to induce metastasis, a process that involves dissoci-
ation of cells from the primary tumor, enhanced cell motility, and
the ability of cells to invade blood vessels and to grow effectively
at distant sites (154).
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FIGURE 3 |Therapeutic effect of relaxin-expressing oncolytic
adenovirus. (A) ECM acts as a physical barrier in solid tumors, so that
interstitial viral penetration and cell-to-cell spread of conventional
oncolytic adenoviruses is restricted to the site of administration,
leading to limited therapeutic efficacy. (B) Relaxin-expressing oncolytic
adenovirus decreases ECM components within a tumor mass and
increases its tumor penetration and dispersion, thereby eliciting
improved antitumor efficacy.
DECORIN-BASED APPROACHES TO INCREASE DRUG PENETRATION IN
SOLID TUMORS
Decorin, a small leucine-rich proteoglycan consisting of a core
protein and a single glycosaminoglycan chain, is a ubiquitous
component of ECM. Decorin has an impact on the production
of several ECM components. For example, it regulates collagen
fibril formation by interacting with collagen fibrils and delaying
the lateral assembly of individual triple helical collagen molecules,
leading to the reduced diameter of the fibrils (169). Decorin also
influences the production of other ECM components by inhibit-
ing the expression of TGF-β, a key profibrotic growth factor (170).
Moreover, decorin has an important role in inducing ECM remod-
eling through promotion of MMP-1 activity (171). These obser-
vations suggest that decorin can modulate tumor ECM produc-
tion and composition at several levels, and hence has an integral
role in degradation and/or downregulation of tumor ECM con-
stituents. Downregulation of TGF-β production by decorin could
also facilitate anti-tumor immune responses through inhibition
of immuno-suppressive T cells (172). In an oncolytic virother-
apy study using decorin, Choi et al. showed that tumor tissue
dispersion by decorin-expressing oncolytic Ad was substantially
enhanced compared with that of control oncolytic Ad, in tumor
spheroids prepared from glioma or breast cancer patients as well as
established subcutaneous human glioma xenograft tumors in vivo
(158). In this study, decorin-expressing oncolytic Ad significantly
reduced ECM components within the tumor tissues while normal
tissue adjacent to the tumor was not affected. Decorin-expressing
oncolytic Ad therefore led to dramatically increased anti-tumor
effect as well as survival benefit in a variety of tumor xenograft
models. Importantly, intratumoral administration of decorin-
expressing oncolytic Ad to the primary tumor site substantially
reduced the formation of B16BL6 melanoma pulmonary metas-
tases in mice, indicating that this approach is capable of inducing
a systemic anti-tumor immune response (158).
STRATEGIES TO OPEN EPITHELIAL JUNCTIONS
JUNCTION OPENERS
Various pathogens must first breach the epithelial barrier before
gaining access to the body in order to initiate infection. Sev-
eral mechanisms to disrupt junctional integrity developed in
these pathogens, e.g.,Clostridium perfringens enterotoxin removes
claudins-3 and -4 from tight junctions to facilitate bacterial inva-
sion (173). Also, zona occludens toxin (Zot) is produced by Vibrio
cholerae strains and possesses the ability to reversibly modify
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intestinal epithelial tight junctions, granting the passage of macro-
molecules through mucosal barriers (174). Notably Cox et al. have
shown that Zot increases the transport of drugs with low bioavail-
ability (e.g., paclitaxel, doxorubicin, acyclovir, and cyclosporin A)
up to 30-fold (175). Additionally, oncoproteins encoded by human
papillomavirus (HPV), human Ad, and human T-lymphotropic
virus 1 (HTLV-1) can transiently open tight junctions by the mis-
localization of the tight junction protein ZO-1, thereby enhancing
paracellular permeability in epithelial cells (176). It is intriguing
that several viruses target epithelial junction protein to achieve
infection of and dissemination in epithelial tissues. Most species
of human adenoviruses (except species B) binds to the CAR. CAR
is a tight junction protein. A number of studies have demon-
strated that during replication of Ad5, excess production of fiber
or fiber/penton base complexes results in the disruption of epithe-
lial junctions either by interfering with CAR dimerization or by
triggering intracellular signaling that leads to reorganization of
intercellular junctions (177, 178). Measles virus uses the adher-
ence junction protein nectin 4 (179). Finally, we have shown that
species B adenoviruses target the desmosomal junction protein
DSG2. To date, however, there are no epithelial junction open-
ers that are being used for cancer therapy. A number of chemical
detergents, surfactants, calcium-chelating agents, and phospho-
lipids have been used to increase drug absorption through the
gastrointestinal (GI) tract epithelium (180). Recently, Kytogen-
ics Pharmaceuticals, Inc., has developed a tight junction opener
based on chitosan derivatives. It is thought to act by electroneg-
ative forces applied to tight junction proteins. However, all of
these agents act indiscriminately to mechanically disrupt junc-
tions and cannot be applied systemically without major toxic side
effects.
AD SEROTYPE 3 DERIVED JUNCTION OPENER JO-1
Human Ads have been classified into 7 species (A to G) cur-
rently containing 57 serotypes. Wang et al. recently reported that
a group of human Ads uses DSG2 as a receptor for infection
(181). Among DSG2-targeting viruses is serotype 3 (Ad3). Ad3
is able to efficiently breach the epithelial barrier in the airway tract
and infect airway epithelial cells. This is achieved by the bind-
ing of Ad3 to DSG2, and subsequent intracellular signaling that
results in transient opening of tight junctions between epithelial
cells. Wang et al. have capitalized on this mechanism and cre-
ated a recombinant protein that contains the minimal structural
domains from Ad3 that are required for opening of the intercellu-
lar junctions in epithelial tumors. This protein is called “junction
opener 1” or “JO-1.” JO-1 is a self-dimerizing recombinant pro-
tein derived from the Ad3 fiber (182). JO-1 has a molecular weight
of approximately 60 kDa (Figure 4A). It can be easily produced
in E. coli and purified by affinity chromatography. JO-1 binding
to and clustering of DSG2 triggers EMT that results in transient
opening of epithelial junctions, in polarized epithelial cancer cells
in vitro (Figures 4B,C) and in vivo, in mouse models with epithelial
tumors. Wang et al. have shown in over 25 xenograft tumor mod-
els that the intravenous injection of JO-1 increased the efficacy of
cancer therapies, including many different monoclonal antibodies
and chemotherapy drugs, in a broad range of epithelial tumors.
Further studies showed that the effective doses of chemotherapy
can be reduced when the chemotherapy drugs are combined with
JO-1. Finally, studies have demonstrated that combining JO-1 with
chemotherapy drugs markedly reduced the toxic side effects of
chemotherapy. The application of JO-1 was safe and well-tolerated
in toxicology studies carried out in human DSG2-transgenic mice
and macaques (109, 181).
Mechanism of JO-1-mediated junction opening
Wang et al. suggested that at least two mechanisms are involved
in JO-1-mediated opening of tight junctions: DSG2 cleav-
age/internalization and EMT-like intracellular signaling. Epithelial
cells are linked to each other by homodimers of DSG2. Studies
in vitro and in xenograft models have shown that the DSG2 ECD
is cleaved upon binding of JO-1, which results in DSG2 internal-
ization (109). On the other hand, a series of data indicate that Ad3
binding triggers EMT-like signaling, which most likely involves
the intracellular domain (ICD) of DSG2. Using mRNA expres-
sion arrays and qRT-PCR, Wang et al. found 12 h after incubation
of polarized breast cancer epithelial cells with a JO-1-like ligand
that 430 genes were upregulated and 352 genes were downregu-
lated compared to incubation with a control protein (181). mRNA
expression profiling revealed the activation of pathways involved
in EMT (MAPK/ERK, adherens junctions, focal adhesion, and reg-
ulation of actin cytoskeleton signaling). Further studies showed an
increase in PI3K and MAPK/ERK1/2 phosphorylation within 1 h
after incubation with Ad type 3 pento-dodecahedral particles or
JO-1 (109, 181). PI3K and MAPK/ERK1/2 activation was signifi-
cantly decreased in cells in which DSG2 expression was suppressed
by siRNA. Beyer et al. also found that subsequently to MAPK and
PI3K activation, the protein levels of E-cadherin, a key junction
protein, decreased in epithelial cells, indicating a down-regulation
of gene expression of junction proteins (109).
JO-1 increases the efficacy of cancer therapy by monoclonal
antibodies and chemotherapy drugs
Beyer et al. have also shown in mouse xenograft tumor models
that the i.v. administration of JO-1-mediated junction open-
ing in epithelial tumors (183). The changes triggered by JO-1
were detectable within 1 h after its i.v. injection. This, subse-
quently, enabled the increased intratumoral penetration of the
anti-Her2/neu mAb trastuzumab (109). These biological effects
of JO-1 translated into an increased therapeutic efficacy of several
mAbs, including trastuzumab and cetuximab, in xenograft tumor
models, e.g., models of colon, breast, gastric, lung, and ovarian
cancer (109). JO-1 co-administration also enhanced the thera-
peutic efficacy of several chemotherapy drugs, including PEGy-
lated liposomal doxorubicin (PLD or Doxil®), paclitaxel (Taxol®),
nanoparticle albumin bound paclitaxel (Abraxane®), and irinote-
can (Camptosar®) in tumor xenograft models of breast, lung, and
prostate cancer (183). Furthermore, chemotherapy doses could
be decreased without compromising the anti-tumor effects due
to JO-1 co-therapy. This also provided protective effects to nor-
mal tissues (183). For example, we showed that the ability of JO-1
to open intercellular junctions in tumors increased the uptake
and amount of chemotherapeutics in the tumor environment
(Figures 5A–C). This then resulted in reduced drug levels in
normal tissues, thereby providing a larger therapeutic window.
Immunofluorescence analysis of tissue sections also revealed
higher levels of PLD in tumors of JO-1+PLD treated mice
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FIGURE 4 | Junction opener 1 (JO-1). (A) Schematic structure of JO-1
The Ad serotype 3 fiber knob domain and one fiber shaft motif was fused
through a flexible linker to a homodimerizing K-coil domain (182). The
protein is self-dimerizing and can be purified by His-Ni-NTA affinity
chromatography. (B) Mode of action. JO-1 binds with picomolar avidity to
DSG2. In epithelial cancer cells, DSG2 is overexpressed and exposed on
the cell surface with preferential localization to desmosomes. JO-1 binding
to DSG2 triggers cleavage of DSG2 dimers between neighboring cells and
the transient activation of EMT pathways. This triggers junction opening
and relocalization of target receptors that are often trapped in epithelial
junctions. Junction opening allows for access of drugs (for example mAbs)
to their target receptors. (C) Transmission electron microscopy of
junctional areas of T84 cells. Cells were either treated with PBS (upper
panel) or JO-1 (lower panel) for 1 h on ice, washed, and then incubated for
15 min at 37°C. At this time, the electron-dense dye ruthenium red (Ru) (1)
was added together with the fixative. If tight junctions (above the
desmosomes) are closed, the dye only stains the apical membrane (black
line). If tight junctions are open, the dye penetrates between the cells and
stains the baso-lateral membrane. JO-1 also mediates the partial
dissociation of desmosomes (D). The scale bar is 0.5µm.
compared to mice treated with PLD alone. In these animals, PLD
is found to be more broadly distributed over a greater distance
from blood vessels, suggesting better intratumoral penetration
and absorption by tumor tissue (Figure 5B). Using an ELISA to
measure PEGylated compounds in tissues (184), we found more
PLD in tumors and less in normal tissues of mice that received
JO-1 prior to i.v. PLD injection (Figure 5C). Better intratumoral
penetration and accumulation of PLD after JO-1-mediated junc-
tion opening, resulted in enhanced therapeutic efficacy of PLD
chemotherapy. This was shown in a model with mammary fat pad
tumors derived from primary ovarian cancer cells (obtained from
a patient biopsy) (135). This cell line was nearly resistant to PLD
injected intravenously at a dose that corresponds to PLD doses
used in patients. Importantly, JO-1 pre-treatment significantly
improved PLD therapy (Figure 5D). JO-1 also relieved adverse
side effects from PLD treatment, e.g., liver enzymes (AST, ALT,
and alkaline phosphatase) were significantly decreased in animals
treated with JO-1 and PLD compared to mice treated with PLD
alone. Mice that received JO-1 injections also had less severe tis-
sue damage in the bone marrow and intestine caused by PLD
treatment (183).
Relocalization of target receptors
In breast cancer xenograft sections and in cultured breast cancer
cells, Beyer et al. found co-staining of Her2/neu and the adherens
junction protein claudin 7 (183). Confocal microscopy of breast
cancer BT474 cells confirmed the trapping of Her2/neu in lat-
eral junctions. Incubation of the Her2/neu positive breast cancer
cell lines BT474 or HCC1954 with JO-1 changed the composi-
tion of the lateral epithelial junctions within 1 h. As a result of
this, Her2/neu staining at the cells surface became more intense,
while it faded in areas distal of the cell surface. This suggests
that JO-1-mediated junction opening triggered a translocation of
Her2/neu from lateral membranes to the cell surface.
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FIGURE 5 | Junction opener 1 increases tumor penetration and
efficacy of PEGylated liposomal doxorubicin (PLD)/Doxil™. Studies
were performed in mice with mammary fat pad tumors derived from
ovc316 cells (135, 206). Ovc316 cells are Her2/neu positive epithelial tumor
cells derived from an ovarian cancer biopsy. (A) Scheme of experiment on
tumor penetration of PLD. Mice were intravenously injected with PBS or
JO-1 (2 mg/kg) followed by PLD or PBS 1 h later. Two hours after PBS or
PLD injection, mice were sacrificed and tumors harvested. (B)
Immunofluorescence analysis for PLD on tumor sections with anti-PEG
antibodies. PLT appears in red. The scale bar is 20µm. Notably, free PEG is
poorly detected by ELISA or immunohistochemistry (184). (C) PLD
concentrations in tumors measured by ELISA (N =3). (D) Therapy study in
mice with ovc316 tumors. Treatment was started when tumors reached a
volume of 100 mm3 (D0). Mice were injected intravenously with 2 mg/kg
JO-1 or PBS, followed by an intravenous injection of PLD (1 mg/kg) or PBS
1 h later. Treatment was repeated weekly (N = 5).
Tumor-specificity of JO-1 action
Junction opener 1 does not efficiently bind to mouse (185), ham-
ster, or dog DSG2 (André Lieber, unpublished data). To perform
efficacy and safety studies in a small animal model, we generated
human DSG2-transgenic mice that expressed human DSG2 at a
level and in a pattern similar to humans (185). Using the hDSG2-
transgenic mouse model with syngeneic hDSG2high tumors, we
demonstrated that JO-1 predominantly accumulates in tumors
(183). This could be explained by either one of the following
factors: (i) the overexpression of DSG2 by tumor cells, (ii) better
accessibility of DSG2 on tumor cells due to a lack of strict cell
polarization compared to DSG2-expressing normal epithelial cells,
or (iii) a high degree of vascularization and vascular permeability
in tumors.
Toxic side effects and immunogenicity
The i.v. injection of JO-1 at a dose of 2 mg/kg into hDSG2-
transgenic mice had no observed adverse side effects, except for
mild, transient diarrhea. There were also no abnormalities found
in laboratory parameters as well as histopathological studies of
tissues. We speculate that this is due to the fact that DSG2 in
tissues, other than the tumor and a subset of epithelial cells
in the intestine/colon, is not accessible to i.v. injected JO-1.
The hDSG2-transgenic mouse model was also used to obtain
biodistribution and pharmacokinetics data for JO-1 (183).
Recently, we started safety studies with JO-1 in macaques. So
far, we injected two animals intravenously with JO-1 at a dose
of 0.6 mg/kg and performed a full necropsy 3 days later. Behav-
ior and health was normal in both animals. In blood and tissue
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analyses, we did not find hematological or histological abnormal-
ities, except for a mild inflammation in the small intestine. JO-1
binding to DSG2 on tumor cells triggers pathways involved in
EMT, a process which, as mentioned above, has been associated
with tumor metastasis. Over 20 in vivo studies conducted with JO-
1 combined with a range of cancer therapeutics in various different
cancers with long-term follow-up, have not provided any evidence
of metastases (183). Transient activation of the EMT pathway is
only one of many steps required for tumor metastasis. Detachment
of tumor cells from epithelial cancers and their subsequent migra-
tion is only possible after long-term crosstalk between malignant
cells and the tumor microenvironment, resulting in changes in
the tumor stroma and phenotypic reprograming of epithelial cells
into mesenchymal cells (186).
Junction opener 1 is a protein derived form Ad3 and there-
fore potentially immunogenic. This might not be a critical issue
if JO-1 is used in combination with chemotherapy, which sup-
presses immune responses (187–189). In addition, Beyer et al.
have shown that JO-1 remains active in vitro and in vivo, even in
the presence of anti-JO-1 antibodies generated by the JO-1 vacci-
nation of mice (183). This may be due to the fact that JO-1 binds
to DSG2 with a very high avidity, thus potentially disrupting the
complexes between JO-1 and antibodies against JO-1. Notably,
JO-1 is a dimer of a trimeric fiber knob, which contributes to the
picomolar avidity to DSG2 (182). Wang et al. performed repeated
injections of JO-1 in an immunocompetent hDSG2 mouse tumor
model to test the effect of anti-JO-1 antibodies on the therapeutic
efficacy of JO-1 (185). Importantly JO-1 had an enhancing effect
on PLD therapy after repeated JO-1 pre-treatment, demonstrating
that JO-1 continues to be effective after multiple treatment cycles,
even in the presence of detectable antibodies.
STRATEGIES TO REMODEL THE TUMOR STROMA THROUGH
TARGETING OF TAMs
As outlined in chapter 1.2, bone marrow-derived cells, including
TAMs, have a pro-tumor effect, in part through the stimulation
of ECM protein synthesis, which in turn blocks intratumoral
penetration of drugs. Therefore, killing of TAMs should, theo-
retically, increase the intratumoral penetration and accumulation
of anti-cancer drugs. TAM depletion results in tumor growth sup-
pression. This has been shown in animal models of cancer by
using transgenic mice (190, 191), clodronate liposome-depletion
of macrophages (192), DNA vaccination against macrophages
(193), and neutralizing antibodies against macrophage chemoat-
tractants (194). For example, Zeisberger et al. showed that combin-
ing macrophage depletion with antibody therapy greatly decreased
the tumor size (195). Furthermore, a recent study showed that
TAM targeting by inhibiting either the myeloid cell receptors
colony stimulating factor-1 receptor (CSF1R) or chemokine (C–
C motif) receptor 2 (CCR2) decreased the number of TICs in
pancreatic tumors, improved chemotherapeutic efficacy, inhib-
ited metastasis, and increased anti-tumor T cell responses (196).
Overall these studies showed that decreasing the number of TAMs
in the tumor stroma effectively altered the tumor microenviron-
ment and markedly suppressed tumor growth and metastasis.
Targeting TAMs did not interfere with the biological functions of
M1 macrophages, including cytotoxicity and antigen presentation.
We are currently attempting to deliver a suicide gene to TAMs
using TAM targeting Ad vectors or the HSC-based approach
described for relaxin gene delivery (157). To restrict suicide gene
expression to TAMs we utilized a miRNA-based system that avoids
transgene expression in other myeloid cells. As a therapeutic gene
for killing TAMs, we are currently focusing on the enzyme cytosine
deaminase, which converts the prodrug 5-Flurocytosine (5-FC) to
the active chemotherapeutic agent 5-Fluorouracil (5-FU) (197).
Toxic 5-FU and metabolites diffuse out of TAMs to surrounding
cells killing TAMs as well as neighboring dividing tumor cells.
STRATEGIES TO INHIBIT EMT TO REMODEL THE TUMOR
STROMA
As outlined above, EMT in solid tumors promotes the expression
of several ECM proteins and thus blocks penetration of anti-
cancer drugs. This give a rationale for inhibiting EMT processes
in epithelial tumors. Accumulating knowledge about EMT path-
ways in solid tumors led to the development of EMT targeted
therapies (198). Classically, such treatment strategies concentrate
on the blockage of ATP-binding sites in affected kinases using
small molecule inhibitors, as the RTK inhibitor Gefitinib for treat-
ment of non-small cell lung cancer with activated EGFR mutation
(199). While originally designed for their anti-proliferative effect
on cancer cells, it was also shown that such molecules can influence
the EMT status. In a cell-based screening of 267 small molecules,
several compounds targeting ALK5, MEK, and SRC kinases were
identified as potent inhibitors of EMT induced by EGF, HGF,
and IGF-1 (200). It was also shown that counteracting TGF-β-
induced EMT by treatment with troglitazone or knockdown of
Smad3 in tumor cells can significantly inhibit experimental metas-
tasis in mice (201). Furthermore, targeting early specific EMT
events, like the degradation of epithelial basement membranes,
can be a successful strategy, as shown in renal interstitial fibrosis.
Deficiency of plasminogen activator (tPA), which is a potent acti-
vator of MMP-9, resulted in stable epithelial basement membranes
and inhibition of EMT (202). Furthermore, studies involving the
expression of pro-epithelial factors such as BMP-7 and Dkk, have
demonstrated the inhibition of EMT and consequent CSC induc-
tion as well as metastasis in colon and prostate cancer models (203,
204). In pioneering work to understand the complexity underly-
ing EMT induction, Scheel and colleagues showed recently that
canonical and non-canonical Wnt signaling cooperate with TGF-
β in order to initiate EMT in breast cancer (205). Consequently,
a series of commercial or experimental Wnt-pathway inhibitors
counteracted EMT. In summary, similar pathways promote ther-
apy resistance, EMT, CSCs, and metastasis. This gives a rationale
to inhibit processes that induce the mesenchymal phenotype of
cancer cells. Clearly, inhibition of EMT must target a variety of
pathways and should only be considered when combined therapy
is applied that targets proliferating cells.
CONCLUSION
Most solid tumors are derived from epithelial cells. Malig-
nant tumor cells actively protect themselves from host-immune
responses and anti-cancer therapeutics by creating physical
barriers that prevent the intratumoral penetration and contact
to malignant cells. This is achieved by the production of cytokines
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and chemokines that attract fibroblasts and myeloid cells into
the tumor and differentiate them into cells that support tumor
growth and produce ECM proteins that shield nests of malig-
nant tumor cells. Furthermore, although malignant cells display a
high degree of dedifferentiation, they maintain epithelial junc-
tions that seal the paracellular space between tumor cells and
block access to tumor antigens or target receptors. Tumor ECM
and epithelial junctions represent the most basic mechanisms that
create resistance to cancer treatment. Because of their impor-
tance to the tumor, they also represent an “Achilles’ heel” that
can be used for cancer therapy. Removal of these barriers will
either directly negatively affect tumor cells or facilitate anti-tumor
immune responses and drug treatment, through better intratu-
moral penetration and accessibility of target cells. A number of
experimental approaches are aimed toward the transient degra-
dation or downregulation of ECM proteins using injection of
ECM-degrading enzymes into the tumor or their intratumoral
expression after viral- or stem cell-based gene transfer. We recently
finished a phase I clinical trial with a relaxin-expressing oncolytic
Ad in patients with recurrent cancer, demonstrating a clinical ben-
efit with a good safety profile. Furthermore, we are focusing on the
clinical development of a recombinant epithelial junction opener
to be used in combination with Doxil chemotherapy in ovarian
cancer patients. Other approaches to overcome physical barriers
in tumors are at a less advanced stage. These approaches attempt
to indirectly decrease tumor-associated ECM by killing tumor
stromal cells that produce ECM proteins (e.g., tumor-associated
fibroblasts or macrophages). ECM production and epithelial junc-
tions can also be targeted through influencing signaling pathways
in tumor cells, specifically pathways involved in the regulation
of EMT/MET and hypoxia. In conclusion, there is an increasing
arsenal of approaches that can be used to enhance the efficacy
of more classical cancer therapeutics and overcome treatment
resistance.
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